INSTRUCTIONS FOR AUTHORS

CANCER RESEARCH is the official organ of the American Association for Cancer Research, Inc., and is devoted to the publication of significant, original research in the fields of cancer research and cancer-related biomedical science. The Editors would be happy to consider manuscripts from any country in the world that contain material falling within the Journal's publication scope. Only those papers that report results of novel and timely studies, and meet high standards of scientific quality will be accepted. Such papers will be published within about three months after acceptance, without charge to authors, except for alterations made in page proof.

When a manuscript is received for consideration, the Editors assume that no similar paper, other than an abstract or preliminary report, has been or will be submitted for publication elsewhere. Editorial decisions, forwarded from the Editorial Office to authors, are rendered as promptly as possible consistent with thoroughness of review. Authors are urged to read carefully and follow these instructions to keep the time and expense involved in processing manuscripts to a minimum.

Contributions must be submitted in triplicate (i.e., the original typescript and two clear copies, with at least two sets of original illustrations) to Dr. Sidney Weinhouse, Editor, CANCER RESEARCH Editorial Office, Fels Research Institute, Temple University School of Medicine, Philadelphia, Pa. 19140 (Telephone: 215-221-4720). Papers should be submitted only by an author, preferably the senior author, who should indicate in a covering letter the exact address to which all related correspondence should be sent and a telephone number at which the author can be reached. If the manuscript contains any quoted information conveyed by either personal communication or release of unpublished experimental data, the covering letter should state specifically that authorization to use this material has been given.

The Editorial Office will not accept the telephone charges for collect calls from authors. Because of the potential expense involved, this policy will be strictly followed.

Revised Manuscripts

Revised manuscripts must be submitted in triplicate. A covering letter must accompany all revised manuscripts to indicate exactly what alterations have (or have not) been made in response to the reviewers' comments. A satisfactory rebuttal is required if authors have not complied with certain of the recommendations.

Categories of Publication

The types of manuscripts accepted are as follows. (1) Papers containing results of original experimental, clinical, or statistical studies that are timely and sufficiently well documented to be acceptable to the critical reader. (2) Concise reviews on subjects of importance to cancer researchers. Such articles are given particularly stringent editorial evaluation before acceptance. (3) Brief Communications of unusual timeliness and significance. These papers are given especially rigid and rapid review and, if deemed acceptable, are published one month earlier than regular papers. These are not to be confused with short papers, which undergo the same review mechanism as regular articles. (4) Letters to the Editor which deal with issues of importance to cancer researchers. If experimental data are included, these should be the minimal amount required for adequate understanding of the paper. (5) Brief reports of meetings and proceedings of symposia related to cancer research. (6) Announcements of future meetings of interest to readers, courses in cancer-related biomedical science, or the availability of fellowships, as well as listings of relevant books and other publications. Announcements should be submitted at least 4 months prior to the expected month of issue.

Format and Style

Papers should conform strictly to Journal style. A recent issue of CANCER RESEARCH will provide authors with assistance in the proper arrangement of papers. Manuscripts are to be written in clear, grammatical, idiomatic English; papers that do not adhere to these requirements will be returned to the author without review, since the Editorial Office does not have the facilities to convert manuscripts to acceptable English standards. Investigators not fluent in the English language can avoid long delays in publication by conferring with colleagues knowledgeable in written English expression in the preparation of their manuscripts.


Data must be presented concisely and clearly. It is important that authors study their typescripts with a view toward elimination of unnecessary words and phrases. Laboratory slang as well as abbreviations not consistent with internationally accepted guidelines are to be avoided. It is in the best interests of the author to read the final typed
copy carefully to detect typographical errors, inconsistencies in the use of tenses, or misleading, ambiguous phrases.

The manuscript should be typed on 21.6- x 28-cm (8-1/2- x 11-inch) paper with double spacing throughout, allowing for ample margins. Consecutive numbering of all pages is requested, with the title page as page 1. The typescript should be arranged in the following order: (a) title, (b) author(s) and complete name(s) and location(s) of institution(s) or laboratory(ies), (c) running title, (d) footnotes, (e) text, (f) tables, (g) legends for all illustrations (charts and figures), (h) illustrations, and (i) other subsidiary material. Numbered and lettered sections in the text should be avoided. The appropriate location for each table and illustration should be indicated by marginal notes. Simple chemical formulas or mathematical equations should be presented in a form that allows their reproduction in single horizontal lines of type; more complicated mathematical formulas or chemical structures which are difficult to set in type should be provided in the form of India ink drawings or glossy photographs for camera-ready reproduction.

**Title.** Titles should be brief but informative, and limited if possible to two printed lines in the Journal. It is important for literature retrieval to include in the title the key words necessary to identify the nature of the subject matter. Use of the expression “Studies on . . .” in titles should be avoided, since it is imprecise and not sufficiently informative. Chemical formulas or abbreviations should not be used. Subtitles, whether set off by Roman numerals or punctuation, are not permitted, as these present difficulties for indexers. If the paper is one of a series, a footnote to this effect may be included.

**Authors and Their Affiliations.** Authors are urged to include their full names, complete with first and middle names or initials. This request is made in accordance with the recommendation of the IUB Commission of Editors of Biochemical Journals because confusion often arises when authors are identified by surname and initials only. Authors' academic degrees should not be included. The full names of institutions and subsidiary laboratories should be given, together with a useful address (including postal number). If several authors and institutions are listed on a paper, it should be clearly indicated with which institution each author is affiliated.

**Running Title.** A brief running title should be provided, not to exceed 50 characters.

**Footnotes.** Lengthy footnotes are discouraged since the same information can in most instances be presented more effectively in the text.

Footnotes to the title page and text are to be designated consecutively with superscript Arabic numerals. A footnote to the title should contain information on financial support, including the source(s) and number(s) of the grant(s). Authors should also include a footnote designating to whom reprint requests should be addressed. An all-inclusive abbreviation footnote should contain a definition for every nonstandard abbreviation used in the paper.

For footnotes to tables, see section on **Tables** below.

**Summary.** The Summary, to appear at the beginning of the paper, should be concise, yet indicative of the content of the paper. As Summaries are often photocopied directly by abstract journals, they should recapitulate in abstract form the purpose of the study and the experimental technique, results, and interpretations of the data. The inclusion of data on the number of test subjects and controls, strains of animals or viruses, drug dosages and routes of administration, tumor yields and latent periods, length of observation period, and magnitude of activity is recommended. Vague, general statements such as “The significance of the results is discussed,” or “Some physical properties were studied,” are uninformative and not acceptable. The use of abbreviations should be limited; if they are needed to keep the Summary short (200-word maximum), they must be properly identified so as to make this section independent of the text.

**Introduction.** It is not necessary to include all of the background literature in this section. Brief reference to the most pertinent papers generally suffices to acquaint the reader with the findings of others in the field and with the problem or question to which the author's particular investigation is being addressed. Large masses of data of peripheral significance to the main thesis of the investigation should not be included. These data may be deposited in the National Auxiliary Publications Service by writing to the American Society for Information Science, 1140 Connecticut Avenue, N.W., Washington, D.C. 20036, and a footnote may be inserted to indicate where this material can be obtained.

**Materials and Methods.** Explanation of the experimental methods should be brief but adequate for repetition by qualified investigators. Procedures that have been published previously should not be described but merely cited in appropriate references. Only new and significant modifications of previously published procedures need detailed exposition. The sources of special chemicals or preparations used should be given with their locations (city and state (country if foreign)).

**Results.** This section should include only statements warranted by previous knowledge and the present observations. Only data necessary for the understanding of the experimental work should be included; it is not necessary to reiterate what is presented in the tables and illustrations. The Results and Discussion sections may be combined if, by so doing, space is saved or the logical sequence of the material is improved. The decision to combine must therefore be made on an individual basis. Authors should bear in mind, however, that many readers prefer to be presented with just the results so that they can draw their own conclusions and then compare them with the author's interpretations in the Discussion.

**Discussion.** The Discussion should interpret the results without repeating information already stated in the Results section. Speculation is permissible, but it must be founded on solid ground and be subject to test. Authors should keep this section brief.

**References.** Any recent issue of the Journal can serve as a model for style of references. It is important that the references be typed in double-spaced form to ensure accurate copy editing. References should be arranged in alphabetical order and should include all authors' names (with
Instructions for Authors

There are several general points about the presentation of manuscripts that should be considered. The bibliography should be limited to include only those citations essential to the author's presentation. When comprehensive review articles are available, their use is preferred to the citation of many separate articles. Authors are responsible for verifying the accuracy of all references and for checking that all references listed have been cited in the text, before submission of their paper to the Journal.

Articles and serial compendia. The complete title, journal, volume number, inclusive pages, and year should be given. Serial compendia, such as Advances in Cancer Research and the Annual Review of Biochemistry, which appear annually in numbered sequence, should be cited as if they were journals rather than books, thus omitting the names of publishers and editors. Chemical Abstracts should be consulted for abbreviations of journals and serials.

Books and chapter citations. Citation of a specific chapter or article in a book should carry the author(s) of the chapter, its title, editor(s) of the book, book title, edition, volume, inclusive pages of the chapter, location and name of the publisher, and year. For references to complete books, give all of the above information that is pertinent.

Papers in press and unpublished material. Papers in press may be listed among the references with the journal name and tentative year of publication. References to papers in preparation or submitted for publication, unpublished data, or personal communications must be cited either parenthetically in the text or in a footnote. Material conveyed by "personal communication" may be used only if permission for its publication and verification of the wording of the citation have been obtained.

Addenda. Data acquired after acceptance of the paper by the authors themselves or by others cannot be added to the text. Insertion of an addendum in proof may be permitted upon approval by the Editors. Addenda should be kept extremely brief; the full expense of printing an addendum will be charged to the author.

Tables. Tables should ordinarily be constructed to fit within a single Journal column (8.9 cm or 3-1/2 inches). If the data require it, however, a table may extend to two columns. Large masses of individual values should be avoided; instead, these should be averaged and an appropriate designation of the dispersion such as standard deviation or standard error included. Authors are obliged to indicate the significance of their observations by appropriate statistical analysis; tables without such information are not acceptable.

Tabular material should not duplicate data already presented in the charts. Unnecessary columns of data that can easily be derived from the rest of the results in the table should not be included.

Every table must have a descriptive title and an explanatory paragraph that clearly gives the experimental details for proper understanding by the reader without reference to the text. Each column must carry an appropriate heading and, if numerical measurements are given, these units should be added to the column heading. Tables should be numbered with Arabic numerals and table footnotes should be indicated with superscript italic letters (a, b, c, etc.).

All units of measurement and concentration should be clearly designated. Exponential terminology is discouraged (the term mm is preferable to 10⁻² M). If exponentials are absolutely unavoidable in column headings, the quantity expressed should be preceded, not followed, by the power of 10 by which its value has been multiplied, i.e., 10⁻² x concentration (M). This will prevent confusion as to whether the quantity should be multiplied or divided to obtain the correct value.

Charts. Line-cut illustrations (graphs and drawings) are to be designated charts. Flow diagrams and complex biochemical structures should be professionally prepared (not simply typewritten) and considered charts. Electrophoretic patterns presented as line-cut drawings are also included in this category; otherwise, they are considered figures.

Graphs should be used sparingly and only when a specific point needs illustration. Straight-line functions such as relationships between concentration and absorbance, or Lineweaver-Burk plots when these are linear, should instead be described in a few lines in the text. To conserve space each chart should include those curves that may appropriately appear together.

The use of exponentials for labeling coordinates in charts is considered ambiguous and should, if at all possible, be avoided. If exponentials must be used, the quantity expressed should be preceded by the power of 10 by which its value has been multiplied, i.e., 10⁻² x concentration (M). The form "Concentration (M x 10⁻²)" is not acceptable. If powers of 10 are used, the legend should designate how the quantity is to be calculated (whether multiplied or divided) to give the correct value.

Preparation of charts. Charts must be drawn with professional instruments and may be on Bristol board, tracing paper or cloth, or coordinate paper printed in light blue. Please do not mount on heavy cardboard. Clear, glossy photographs are acceptable in lieu of original drawings, provided that all parts of the chart are in focus. X-ray films or Polaroid photographs are not acceptable. If original drawings are submitted, an overall size of not more than 21.6 x 28 cm (8-1/2 x 11 inches) is required.

Except for especially complicated drawings showing large amounts of data, all charts will be reduced to one-column width (8.9 cm or 3-1/2 inches) or less. It is the responsibility of the author to see that the abscissas, ordinates, lines, and especially the symbols are sufficiently large so that, when the charts are reduced to the size of a single column (8.9 cm or 3-1/2 inches), the letters and numbers will be at least 1.5 mm high and the smallest part of the illustration will be discernible. In original charts, this can be accomplished by having the minimum height for lower-case letters 5 mm; numerals and upper-case letters 6 mm; and symbols within the drawings 5 mm. The thickness of ruled lines on charts is also vital for clear presentation of the data. Size recommendations for lines are as follows: #1 Leroy for graph grids, bonds, and arrows; #2 Leroy for graph borders or reference lines; and #5 Leroy for graph curves or emphasis lines.

Points of observation should be denoted with different
symbols rather than with different types of lines; their significance can be explained directly in the body of the chart or in the legend. Only those common symbols for which the printer has type (×, ○, ●, □, ■, △, ▲, ◆) should be used.

Charts should be ruled off on all four sides close to the area occupied by the curve, and abscissas and ordinates should be clearly marked with appropriate units. Explanations of the coordinates should not extend beyond the respective lines. If the chart contains a left- and right-hand ordinate, explanation of the left ordinate should read in the upward direction and that of the right ordinate should read downward. Titles printed outside the confines of the charts only waste space and should not be used; all of this information can easily be included in the legend to the chart.

Each chart should be labeled on the reverse side with Arabic numerals and the first author’s name.

Chart legends. Legends are required for all charts. They should be sufficiently informative to be intelligible to the reader; descriptive details need not be repeated in the text. Each legend should adequately identify all units, mathematical expressions, abscissas, ordinates, and symbols.

Figures. Because halftone illustrations (photomicrographs and photographs) are expensive to reproduce, only those photographs that are absolutely essential to the clarity of the presentation can be accepted.

Photographed electrophoretic patterns should be submitted as small as possible to avoid the need for returning them to the author for reduction.

Color photographs are discouraged and will be published only if they are indispensable. If after careful evaluation these are accepted by the Editors, the complete expense of reproducing such photographs will be charged to the author. Current estimates for color reproduction can be obtained by corresponding with the Editor.

Preparation of plates. Photographs should be mounted on “plates” of white cardboard not larger than 8.4 x 22.4 cm (7-1/4 x 9 inches). All photographs should be correctly exposed, sharply focused, and submitted on glossy white paper. Considerable space may be saved by suitably cropping figures so that 4 to 6 photographs can be presented on one plate. Plates with only single photographs are not acceptable and will be returned for cropping or reduction unless the authors can justify their necessity unequivocally.

Tooling (thin white lines) between the photographs should be uniform. Figure numbers, in Arabic numerals, should appear in India ink directly on the photographs and, if possible, should be in the lower right-hand corner of each photograph. Wax-based lettering such as PRES-TYPE or LETTTRA-SET is discouraged because of its tendency to crumble and adhere to vinyl overlays. Tissue overlays on plates are a necessary protection for figures. The first author’s name should be given on the reverse side of each plate.

Figure legends. An appropriate legend for each figure, including stains and magnifications where applicable, is required. Any abbreviations or reference point on a figure should be explained in the legend.

Abbreviations

Abbreviations are in general a hindrance to readers in fields other than that of the author(s), to abstractors, and to scientists in foreign countries. It is therefore the policy of this Journal, which publishes materials on several subspecialities of cancer research, to reduce their use to an absolute minimum. Short terms need not be abbreviated, e.g., daunomycin, folate, vincristine. Abbreviations are not to be used in titles, but running titles may carry abbreviations for purposes of brevity. In the Summary, abbreviations for terms mentioned many times in that section can be used, but only if clearly identified.

Authors should follow the recommendations of the IUPAC-IUB Commission on abbreviations (see section below on Terminology). All nonstandard abbreviations should be identified in an inclusive abbreviation footnote to the first such abbreviation after the Summary.

Avoid using abbreviations that form recognizable words, such as EAT, MOPS, ALL, etc., or those that repeat standard abbreviations.

Standard Abbreviations. Authors may use, without definition, the abbreviations in the following list.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPN⁺, DPNH</td>
<td>diphosphopryidine nucleotide and its reduced form</td>
</tr>
<tr>
<td>TPN⁺, TPNH</td>
<td>triphosphopyridine nucleotide and its reduced form</td>
</tr>
<tr>
<td>NAD⁺, NADH</td>
<td>nicotinamide adenine dinucleotide and its reduced form</td>
</tr>
<tr>
<td>NADP⁺, NADPH</td>
<td>nicotinamide adenine dinucleotide phosphate and its reduced form</td>
</tr>
</tbody>
</table>

(please note that DPN⁺-DPNH, NAD⁺-NADH, and TPN⁺-TPNH, NADP⁺-NADPH are paired abbreviations for the oxidized and reduced forms of the same substances. Either system is acceptable, but both systems should not be used interchangeably in the same manuscript.)

CoA, acyl-CoA  coenzyme A and its acyl derivatives (e.g., acetyl, etc.)

AMP, GMP, IMP, UMP, CMP, TMP  the 5'-phosphates of the ribonucleosides of adenine, guanine, hypoxanthine, uracil, cytosine, and thymine

ADP, etc.  the 5'(pyro)-diphosphates of adenosine, etc.

ATP, etc.  the 5'(pyro)-triphosphates of adenosine, etc.

dAMP, dGMP, dIMP  the 5'-phosphates of 2'-deoxyribosyladenine, etc.

RNA, DNA  ribonucleic acid, deoxyribonucleic acid

RNase, DNase  ribonuclease, deoxyribonuclease

mRNA  messenger RNA

nRNA  nuclear RNA

rRNA  ribosomal RNA

tRNA  transfer RNA (sRNA is not recommended for RNA preparations)
Other Standard Abbreviations.

**Units of Concentration**
- molar (mole/liter) = M
- millimolar (m mole/liter) = mM (preferred to 10^{-3} M)
- micromolar (μmole/liter) = μM (preferred to 10^{-6} M)
- nanomolar = nM (not μM)
- picomolar = pM (not μM)

The expression mg % should be avoided; weight concentrations should be given as g per ml, g per 100 ml, g per liter, etc.

**Units of Length, Area, Volume, Mass, Time**
- meter = m
- centimeter = cm
- square centimeter = sq cm
- millimeter = mm
- micrometer (not micron) = μm (not μ)
- nanometer (not millimicron) = nm (not μm)
- picometer (not micromicron) = pm (not μm)
- Angstrom (0.1 nm) = Å
- milliliter = ml (use instead of cc or cm^3)
- microliter = μl (not λ)
- gram = g
- milligram = mg
- microgram = μg (not γ)
- kilogram = kg
- hour(s) = hr
- minute(s) = min
- second(s) = sec
- counts per minute = cpm
- disintegrations per minute = dpm
- revolutions per minute = rpm
- Curie = Ci
- Svedberg unit = S
- mole = not abbreviated

**Physical and Chemical Units**
- retardation factor = R
- acceleration of gravity = g
- sedimentation coefficient = s
- sedimentation coefficient in water at 20°C = s_{20, w}
- degree Celsius (Centigrade) = °C (not °C)
- degree Kelvin (absolute temp.) = °K
- diffusion coefficient = D
- equilibrium constant = K
- inhibition constant = K_i
- Michaelis constant = K_m
- maximum velocity = V_{max}

**Others**
- absorbance = A (not O.D.)
- probability = p
- roentgen = R
- standard deviation = S.D.
- standard error of the mean = S.E.
- logarithm (Briggsian) = log
- logarithm (natural) = ln
- in chemical compounds
  - ortho = o
  - meta = m
  - para = p
  - secondary = sec
  - tertiary = tert
- routes of administration
  - intramuscular = i.m.
  - intraperitoneal = i.p.
  - intravenous = i.v.
  - oral = p.o.
  - subcutaneous = s.c.

**Terminology**

The IUPAC-IUB Commission on Biochemical Nomenclature has published collected tentative rules and recommendations of approved terms and abbreviations for chemical substances, which are now available for $2 (to accompany order) from the American Society of Biological Chemists, Inc., 9650 Rockville Pike, Bethesda, Maryland 20014. Individual listings have appeared in many journals as follows:

- for nucleic acids, polynucleotides, and their constituents,
Instructions for Authors


Isotopically Labeled Compounds. A radioactive nuclide is indicated by its mass number as a superscript to the left of the symbol (32P); when written out, it should correspond to the spoken word (phosphorus-32).

In an isotopically labeled compound, the isotopic prefix should be placed in square brackets and immediately precede the name (word) to which it refers, as in [14C]thymidine, [α-14C]leucine, t-[methyl-14C]methionine. When more than one position in a substance is labeled by means of the same isotope and the positions are not indicated, the number of labeled atoms is added as a subscript to the right of the element, as in [14C2]glycolic acid. The symbol U indicates uniform labeling and G, general labeling, e.g., [U-14C]glucose (where the 14C is uniformly distributed among all six positions) and [G-14C]glucose (where the 14C is distributed among all six positions, but not necessarily uniformly); in the latter case it is often sufficient to write simply [14C]glucose.

The isotopic prefix precedes that part of the name to which it refers, as in sodium [14C]formate, iodod[14C]acetate, 1-amino[14C]methylcyclopropanol, α-naphth[14C]acetic acid, 2-acetamido-7-[131I]iodofluorene, fructose 1,6-[132P]diphosphate, 17β-[3H]estradiol, Escherichia coli [3H]DNA. Terms such as “[3H]-labeled albumin” should not be contracted to “[3H]-albumin” (since native albumin does not contain iodine), and “[14C]-labeled amino acids” should similarly not be written as “[14C]amino acids” (since there is no carbon in the amino group).

When isotopes of more than one element are introduced, their symbols should be arranged in alphabetical order, e.g., [3-14C, 2,3-D, 15N]serine. Deuterium and tritium may be designated by the systems, 2H and 3H or D and T, respectively.

When not sufficiently distinguished by the foregoing means, the positions of isotopic labeling are indicated by Arabic numerals, Greek letters, or prefixes in italics, as appropriate; these are to be placed within square brackets to appear before the symbol of the element concerned and are attached to it by a hyphen. Examples of this style are [1-14C]labeled, t-[2-14C]leucine or l-[α-14C]leucine, [carboxy-14C]leucine, [2,3-14C]maleic anhydride, [3,4-14C, 32S]methionine, t-[methyl-14C]methionine. The symbol indicating configuration always precedes the bracketed isotope, and a hyphen is used to separate it from the brackets, e.g., D-[14C]glucose; l-[1-14C]leucine; (R)-[14C]-ethanol.

The same rules apply when the labeled compound is designated by a standard abbreviation or symbol other than the atomic symbol, e.g., [α-32P]ATP, [32P]CMP, or [131I]-IUDR. The square brackets are not to be used, however, for simple molecules, or when the isotopic symbol is attached to a word that is not a specific chemical name, abbreviation, or symbol. Examples of these types are as follows: 14CO2, 32O, H2O, H3SO4, 32P, [131I]-labeled, 3H-ligands, [14C]-steroids.

Enzymes. Authors should use the Recommended (trivial) Name given by the IUB Commission on Enzyme Nomenclature Recommendations (1972) of the International Union of Pure and Applied Chemistry and the International Union of Biochemistry (Elsevier Publishing Company, Amsterdam, 1973). In some cases the Systematic Name or the reaction catalyzed should also be included.

For information on isozyme nomenclature, consult the “Collected Tentative Rules . . .” mentioned above or the specific listing published in the Journal of Biological Chemistry (reference above).

Histones. Histone nomenclature should conform to the following system proposed at a recent Ciba conference held on April 4–5, 1974, in London: the six histone fractions are to be labeled H1, H1*, H2A, H2B, H3, and H4, rather than F1, F1*, F2a2, F2b, F3, and F2a1, respectively.


Drugs. Generic names of drugs are preferred; a proprietary name may be used only after the first mention of the generic name and should be avoided in titles unless both names can easily be listed. If a foreign proprietary name is used, the name of the comparable U. S. product should be given. When there is no generic name for a drug, authors should give the chemical name or formula or a description of the active ingredients.

Authors should refer to the formally adopted generic names listed in Drug Evaluations, Pharmacopeia of the United States (USP), National Formulary (NF), and United States Adopted Names (USAN). In addition, the Council on Drugs reports in The Journal (New Names) drug names adopted by the USAN Council. These monographs include both the generic and proprietary names for the newest drugs, usually prior to their publication elsewhere.
Tumors. Tumors used in experimental investigations should be clearly described and identified in acceptable terminology. If these tumors are well known and have been readily identified in previous publications, extended descriptions and photomicrographs are unnecessary.

General. The composition of all solutions and buffers should be specified in sufficient detail so that the concentration of each component can be determined. The word “saline” should be replaced by “NaCl solution,” along with the exact concentration. Inexact terms such as “physiological saline” or “phosphate-buffered saline” are not permitted; exact contents and concentrations should be given.

Decimals are preferred to fractions; the form 0.01, not .01, is required in text, tables, and charts.

Ionic charge should be designated by a superscript immediately following the chemical symbol, e.g., Mg++, S~.

Advice on biochemical nomenclature is readily available from Dr. Waldo E. Cohn, Director, NAS-NRC Office of Biochemical Nomenclature, Biology Division, Oak Ridge National Laboratory, Box Y, Oak Ridge, Tennessee 37380.

Alterations in Proof

To expedite publication of accepted articles, the Journal is now providing authors with page proofs only. Extensive alterations in proof require revised pagination, thus leading to sharply increased costs and delays in publication. Such alterations will necessarily be charged to the authors. We therefore urge our contributors to proofread and edit their manuscripts carefully before submission. If authors make an inordinate number of corrections in page proof, or if proof is not returned to the Editorial Office within 48 hours of receipt, it may be necessary to reschedule the paper to a subsequent issue.

Reprints

Reprints are to be ordered prior to publication according to the schedule of prices that accompanies the page proof. If the reprint order form has been omitted inadvertently from the shipment, the Editorial Office should be contacted immediately.

Requests for additional reprints should be addressed directly to the printer, Waverly Press, Inc., Mount Royal & Guilford Avenues, Baltimore, Maryland 21202. Reprints ordered after the Journal has been released to press will be more costly.

It is helpful to those requesting reprints if a footnote is inserted indicating to which author reprint requests should be addressed.

Subscriptions and Business Inquiries

All subscriptions and business matters are handled by the publisher, The Williams & Wilkins Co., 428 East Preston Street, Baltimore, Maryland 21202.

Reproduction Permission

Reproduction permission by Cancer Research, Inc., of copyrighted material requested for legitimate purposes will not be withheld from the authors or other individuals. Requests for such reproduction, with a brief description of intended use, should be made by writing to the Editor. Third parties should obtain the approval of the authors before corresponding with the Editor.

No responsibility is accepted by the Editors, by Cancer Research, Inc., or by the publishers of CANCER RESEARCH for opinions expressed by contributors.

The Editorial Staff of CANCER RESEARCH has noticed that several items are commonly overlooked by authors, entailing wasted time and expense at the processing and publication stages. Authors may find it helpful to refer to the following checklist before transmitting their manuscripts to our office.

1. Manuscript submitted in triplicate with two sets of original illustrations
2. Instructions regarding sequence of text sections followed
3. Grant information, if appropriate, supplied in a footnote to the title
4. Exact affiliation of each author given
5. Running title provided, not to exceed 50 typed characters
6. Summary included
7. All nonstandard abbreviations defined in an inclusive footnote
8. Exact location [city and state (or country)] supplied for all commercial suppliers
9. All references listed in alphabetical order and typed double spaced
10. Instructions followed regarding size of lettering on charts
11. Electron micrographs mounted on heavy white cardboard not to exceed 18.4 x 22.4 cm (7-1/2 x 9 inches)
AUTHOR INDEX
July 1975

Abraham, S., 1649
Allen, P. T., 1854
Altmann, A. J., 1809
Angellis, D., 1706
Baehner, R. L., 1809
Barber, S., 1649
Bartley, J. C., 1649
Beard, D., 1603
Beard, J. W., 1603
Becker, F. F., 1734
Benjamin, S. A., 1745
Berman, E., 1887
Boecker, B. B., 1745
Boutwell, R. K., 1662
Bowen, J. M., 1854
Brooks, S. C., 1791
Buchsbaum, R. N., 1865
Caleb, M. H., 1861
Centifanto, Y. M., 1880
Chan, J. C., 1854
Chang, C-H., 1706
Chen, J.-H., 1767
Chiffelle, T. L., 1745
Christensen, A. K., 1671
Clark, B. R., 1727
Cleaver, J. E., 1773
Cohen, D., 1779
Cox, R., 1858
Crussi, F. G., 1809
DeVald, B. L., 1830
Dmochowski, L., 1854
Doellgast, G., 1706
Donnbach, R. C., 1737
Dryle, D. M., 1880
Dunning, W. F., 1840
East, J. L., 1854
Egan, M. L., 1804
Feldman, M., 1840
Fink, L. M., 1887
Fishman, W. H., 1706
Furner, R. L., 1799
Gantt, R., 1847
Godefroi, V. C., 1791
Goldenberg, G. J., 1687
Gotohda, E., 1628
Grindey, G. B., 1702
Haber, M., 1779
Hacker, M., 1756
Hahn, F. F., 1745
Halpern, R. M., 1727
Harris, J. P., 1861
Hayano, K., 1643
Heine, U., 1603
Hillman, E. A., 1603
Hobbs, C. H., 1745
Holland, J. F., 1767
Huseby, R. A., 1671
Irving, C. C., 1858
Jones, R. K., 1745
Julian, B. T., 1847
Kakunaga, T., 1637
Kamiyama, M., 1713
Kaufman, H. E., 1880
Kirch, D., 1761
Knesek, J. E., 1854
Kobayashi, H., 1628, 1718
Koch, M. R., 1693
Kodama, T., 1628
Kurland, G., 1671
Kuroki, T., 1819
Kuzumaki, N., 1628, 1718
Kwock, L., 1826
Lapis, K., 1603
Lea, M. A., 1693
Leighton, J., 1873
Locke, E. R., 1791
Martin, D. H., 1654
Martinez-Hernandez, A., 1887
McClellan, R. O., 1745
McManus, L. M., 1887
Mellett, L. B., 1799
Merrill, D. A., 1887
Miller, M. S., 1826
Mills, P. A., 1727
Miyashita, S. Y., 1819
Mizuno, K., 1643
Moran, R. G., 1702
Morris, H. P., 1693
Morris, J. E., 1804
Murai, J. T., 1727
Naughton, M. A., 1887
O’Brien, T. G., 1662
Ohnuma, T., 1767
Painter, R. B., 1773
Pazmiño, N., 1654
Pierce, G. E., 1830
Pomeranz, A., 1727
Raam, S., 1706
Racker, E., 1865
Rierden, W. J., 1809
Roberts, D. 1756
Robinson, E., 1779
Sakaguchi, K., 1643
Sakiyama, H., 1723
Schreiber, H., 1654
Sekiya, S., 1713
Simsaiman, R. C., 1662
Singh, D. V., 1791
Sirotnak, F. M., 1737
Smith, G. H., 1847
Smith, R. A., 1727
Snipes, M. B., 1745
South, M. A., 1861
Stewart, I., 1761
Suolimna, E.-M., 1865
Taguchi, T., 1698
Takamizawa, H., 1713
Takeda, Y., 1698
Takeichi, N., 1628
Tavel, A., 1761
Tei, N., 1698
Terasima, T., 1723
Terman, D. S., 1761
Todd, C. W., 1804
Tominaga, T., 1698
Toyoshima, K., 1873
Tsujino, M., 1643
Vera, N., 1854
Voigt, W., 1840
Wallach, D. F. H., 1826
Weiss, D. W., 1779
White, M. J., 1887
Yoshizawa, M., 1643
Yron, I., 1779
Yuasa, Y., 1819
Zam, Z. S., 1880
Zeiger, E., 1813
The annual checkup. It may save your life.

Even though you feel fantastic, there's only one way to be sure you're in perfect health. Have an annual checkup. The annual checkup is a complete, head-to-toe examination.

By taking a blood count, doing a Pap test for women, giving you a procto, and doing all the other important things that make up a complete examination, your doctor can discover if you're as well as you feel.

The annual checkup gives your doctor a good chance to catch a minor ailment before it becomes a major illness. Or a fatal one.

We want to wipe out cancer in your lifetime.

Give to the American Cancer Society.